MBLi program

MBLi: Metallo Beta-Lactamase inhibitor

ANT2681 is a novel and potent metallo ß-lactamase (MBL) inhibitor that displays excellent activity against NDM carrying carbapenem-resistant Enterobacterales (CRE). It will be administered intravenously in conjunction with meropenem for the treatment of NDM -CRE, which are prevalent throughout China and the Asia Pacific region and for which no inhibitors are currently available. ANT2681 has received QIDP status from the FDA for complicated urinary tract infections (cUTI). Preclinical development has been completed and the program is ready for progression to Phase I.